Celltrion’s Autoimmune Disease Biosimilar Expands Indication for Pediatric Intestinal Disease in Europe
3 Articles
3 Articles
Celltrion’s biosimilar autoimmune disease treatment, ‘Stekima,’ is expected to expand its prescription scope to include pediatric inflammatory bowel disease in Europe. The company received a recommendation for approval from European regulatory authorities to extend the treatment of Crohn’s disease and ulcerative colitis, which was previously focused on adults, to children aged two and older. Celltrion stated that Stekima, a biosimilar of ‘Stelar…
Celltrion wins European recommendation to expand Steqeyma’s pediatric indications
Pictured above is the head office of Celltrion in South Korea. [Photo courtesy of Celltrion] South Korea’s Celltrion announced on Nov. 9 that it has received a positive recommendation from a European regulatory committee to expand the approved uses of its autoimmune disease treatment Steqeyma to younger pediatric patients. The pharmaceutical company noted that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) …
Addition of indications for Crohn's disease and ulcerative colitis... Expansion of prescription scope
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
